TABLE 1.

Demographic, clinical, and virological characteristics of the study population

Subjecta	Age (yr)	Ethnicityb	Enrollment time point			Sampling time point				HLA class I type
			Days postinfection	HIV-1 RNA copies/ml	CD4+ T cells/mm3	Days postinfection	Treatment duration (days)	HIV-1 RNA copies/ml	CD4+ T cells/mm3	A	B	Cw
1188	23	H	79	73,074	409	93	5	<500	375	23	35, 15	02, 07
1212	37	C	11	5,060,000	757	16	Noc	102,045	925	02, 23	44, 62	03, 04
1216	33	C	129	26,000	300	134	2	38,400	255	03, 24	07, 39	07
1238	42	C	45	99,600	367	45	No	99,600	367	01, 03	07, 14	07, 08
1242	30	C	42	96,900	874	105	57	343	787	03, 33	14, 35	04, 08
1362	24	C	8	8,240,000	878	8-680	No	117,077	871	02, 25	18, 51	01, 12
1484	27	C	12	4,340,700	300	19	No	4,340,700	830	02, 03	07, 35	04, 07
1490	41	C	55	286,272	568	62	No	286,272	568	02, 11	15, 35	03, 04
1509	37	C	191	271	486	343	No	65	426	01, 02	15, 57	03, 06
1576	32	C	22	3,717,000	332	63	42	4,129	552	11, 33	49, 51	07, 15
1577	32	C	89	701	746	177	No	24	603	2	27, 49	02, 07
1585	39	C	123	58	659	150	No	56	554	10, 68	03	03, 06
1596	36	C	19	260,605	700	20	No	260,605	265	03, 26	38, 35	04,12
1599	30	C	46	404,463	265	46	No	404,463	265	01, 02	08, 18	7
1686	38	H	55	155,545	186	70	No	219,312	241	23, 25	35, 40	03, 04
1689	28	H	11	2,240,958	1206	11	No	94,708	745	02, 03	35, 40	03, 04
1690	42	C	21	1,031,477	396	21	No	400,163	528	01	08	07
1691	23	B	29	26,713	694	29	No	7,382	758	30	42, 53	06, 17
1692	42	B	50	2,461	612	50	No	2,461	612	23, 30	08, 42	07, 17
1693	41	H	7	377,063	559	7	No	1,912,195	472	01, 03	08, 35	04, 07
1698	45	H	11	734,413	458	11	No	262,437	531	NTd	NT	NT
1699	43	C	28	215	1,94	28	No	296	945	01, 02	08, 57	06, 07
1706	28	C	25	354,860	420	25	No	6,457	521	02, 32	08, 55	03, 07

^aAll subjects were male.

^bEthnicity: C, Caucasian; H, Hispanic; B, black.

^cNo, no treatment.

^dNT, not tested.